Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
The purpose of this study is to determine if low-dose imatinib and nilotinib combination,
 will improve treatment results in CML patients with failure, suboptimal response or
 intolerance to imatinib therapy.

 The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular
 response will be achieved in patients not previously obtained with imatinib monotherapy.
Inclusion Criteria:

 -  CML patients with failure or suboptimal response to imatinib therapy according to
 criteria established by the European Leukemia Net (ELN)

 -  Patients with grade II or higher adverse events.

 -  CML patients not suitable for stem cell transplantation.

 Exclusion Criteria:

 -  Patients in blast crisis.

 -  Pregnant women

 -  Patients without a contraception method.